Megestrol acetate NCD oral suspension - Par Pharmaceutical

Drug Profile

Megestrol acetate NCD oral suspension - Par Pharmaceutical

Alternative Names: Megace ES oral suspension; Megestrol acetate NanoCrystal® Dispersion oral suspension; Megestrol Alkermes; PAR-100.2

Latest Information Update: 16 Nov 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Par Pharmaceutical
  • Class Antiandrogens; Antineoplastics; Pregnadienes; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Anorexia; Cachexia

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 05 Nov 2015 Par Pharmaceutical Inc has been acquired by Endo International
  • 28 Jul 2015 First generic equivalent available in USA for Anorexia and Cachexia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top